Enicepatide
A weekly GLP-1/GIP dual agonist built to signal without pulling its receptors inside the cell; Roche began phase 3 trials in 2026.
Enicepatide (CT-388) is a once-weekly peptide that activates the GLP-1 and GIP receptors while causing little receptor internalisation; in a four-week phase 1 study, people with overweight or obesity lost 4.7% to 8.0% of body weight against 0.5% on placebo (PMID 41319798), and Roche's Enith phase 3 programme started in March 2026.
Used in human trials: 5–12 mg, once weekly for four weeks, subcutaneous (Studied dose) Details ↓
Recommended Dosing
Used in human trials
No manufacturer dose exists for this use: these are amounts given in published trials, not recommendations.
Mechanism of action
Activates the GLP-1 and GIP receptors in one molecule, the same pair tirzepatide targets. In cell assays it was biased toward cAMP signalling at both receptors and caused minimal receptor internalisation compared with the native hormones; the developer's hypothesis is that receptors left on the cell surface keep responding (PMID 41319798).
Primary uses
- Obesity and overweight (phase 3)
- Obesity or overweight with type 2 diabetes (phase 2 complete)
Typical dosing
Phase 1 doses: single injections of 0.5 to 7.5 mg, then four weekly doses of 5 to 12 mg in otherwise healthy people with overweight or obesity (PMID 41319798). Study amounts, not recommendations; phase 3 doses are not published.
Educational information, not medical advice. The doses on this page come from approved labels, published studies and, where no study exists, amounts reported by users. None is a recommendation for you. An unapproved compound has no established safe or effective human dose, and products sold for “research use only” are not made or tested for people. Talk to a doctor before acting on anything on this site, including before you start, stop or change any medicine or dose. Full medical disclaimer.
Regulatory status
Not approved anywhere. Phase 3: Enith1 (NCT07351045, 2,000 planned) and Enith2 (NCT07351058, 1,600 planned), both in adults with obesity or overweight, started in March 2026. Two 48-week phase 2 trials are complete, one in obesity (NCT06525935, completed December 2025) and one in type 2 diabetes (NCT06628362); neither had posted or published results when read (October 30, 2026).
Status as of this entry's last review, October 30, 2026. Approvals, compounding rules and sport rules change; the regulatory tracker is checked more often.
What the studies show
One paper on PubMed reports enicepatide in people; the two completed phase 2 trials and the phase 3 trials have no published results yet.
Human · 2026
Effects of CT-388, a once-weekly signaling-biased dual GLP-1/GIP receptor agonist, on weight loss and glycemic control in preclinical models and participants with obesity
Cell, mouse and monkey work plus a randomised phase 1 trial (NCT04838405). Four weekly doses of 5 to 12 mg lowered body weight by 4.7% to 8.0% at day 29, against 0.5% on placebo; most adverse events were mild or moderate and gastrointestinal, as with other incretin drugs.
Registry · 2024
Phase 2 in obesity
A 48-week phase 2 trial of five weekly dose levels against placebo in 469 people with obesity or overweight and at least one weight-related condition; completed in December 2025, with no results posted or published by October 30, 2026.
NCT06525935 · ClinicalTrials.gov record
Registry · 2026
A Phase III, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Once-Weekly RO7795068 Administered to Participants With Obesity or Overweight Without Type 2 Diabetes
Enith1: a 2,000-person phase 3 trial of three weekly dose regimens against placebo in obesity or overweight without diabetes, recruiting since March 2026, primary completion expected July 2028.
NCT07351045 · ClinicalTrials.gov record
References
- [pubmed] Chakravarthy MV, et al. "Effects of CT-388, a once-weekly signaling-biased dual GLP-1/GIP receptor agonist, on weight loss and glycemic control in preclinical models and participants with obesity." Mol Metab, 2026;103:102291. PMID: 41319798.
- [clinicaltrials] ClinicalTrials.gov NCT07351045: "A Phase III, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Once-Weekly RO7795068 Administered to Participants With Obesity or Overweight Without Type 2 Diabetes" Hoffmann-La Roche. Phase 3, recruiting, March 2026 to July 2028 (primary completion), 2000 participants. Registry record read October 28, 2026.
- [clinicaltrials] ClinicalTrials.gov NCT06628362: "A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multi-Center Phase 2 Study to Evaluate the Efficacy, Safety, and Tolerability of Once-Weekly CT-388 Administered Subcutaneously for 48 Weeks to Participants Who Are Overweight or Obese With Type 2 Diabetes Mellitus" Carmot Therapeutics, Inc.. Phase 2, completed, November 2024 to May 2026 (primary completion), 447 participants. Registry record read October 28, 2026.
- [clinicaltrials] ClinicalTrials.gov NCT06525935: "A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multi-Center Phase 2 Study to Evaluate the Efficacy, Safety, and Tolerability of Once-Weekly CT-388 Administered for 48 Weeks to Participants With Obesity or Overweight With at Least One Weight-Related Comorbidity" Carmot Therapeutics, Inc.. Phase 2, completed, August 2024 to December 2025, 469 participants. Registry record read October 30, 2026.
- [clinicaltrials] ClinicalTrials.gov NCT07351058 (Enith2): phase 3 study of once-weekly enicepatide (RO7795068) in participants with obesity or overweight. Hoffmann-La Roche. Recruiting, March 2026 to August 2028 (primary completion), 1,600 participants planned. Registry record read October 30, 2026.
Related peptides
Guides & tools
This entry is for educational purposes only and does not constitute medical advice. Dosing information reflects published regulatory or research data and is not a recommendation. Many compounds described here are not approved for human use in the United States. Consult a licensed medical professional before considering any peptide therapy.